Kiniksa Pharmaceuticals Ltd Market Cap ($4.71 Billion)
Market Cap & Net Worth: Kiniksa Pharmaceuticals Ltd (KNSA)
Kiniksa Pharmaceuticals Ltd market cap. Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) has a market capitalization of $4.71 Billion ($4.71 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3613 globally and #1294 in its home market, demonstrating a 22.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kiniksa Pharmaceuticals Ltd's stock price $97.56 by its total outstanding shares 48289273 (48.29 Million).
Kiniksa Pharmaceuticals Ltd Market Cap History (2018–2026)
Kiniksa Pharmaceuticals Ltd market cap history from 2018 to 2026. Data shows growth from $1.36 Billion to $4.71 Billion (21.04% CAGR). Check Kiniksa Pharmaceuticals Ltd (KNSA) stock price for real-time trading data and today's change.
Index Memberships
Kiniksa Pharmaceuticals Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.18% | #95 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.01% | #419 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.26% | #63 of 263 |
Weight: Kiniksa Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kiniksa Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kiniksa Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Kiniksa Pharmaceuticals Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
2.94x
Kiniksa Pharmaceuticals Ltd's market cap is 2.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
33.76x
Kiniksa Pharmaceuticals Ltd's market cap is 33.76 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $853.27 Million | $7.70 Million | -$161.38 Million | 110.76x | N/A |
| 2021 | $568.36 Million | $38.54 Million | -$157.92 Million | 14.75x | N/A |
| 2022 | $723.37 Million | $220.18 Million | $183.36 Million | 3.29x | 3.95x |
| 2023 | $846.99 Million | $270.26 Million | $14.08 Million | 3.13x | 60.14x |
| 2024 | $955.16 Million | $423.24 Million | -$43.19 Million | 2.26x | N/A |
| 2025 | $1.99 Billion | $677.56 Million | $59.01 Million | 2.94x | 33.76x |
Competitor Companies of KNSA by Market Capitalization
Companies near Kiniksa Pharmaceuticals Ltd in the global market cap rankings as of October 31, 2026. See KNSA net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Kiniksa Pharmaceuticals Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of Kiniksa Pharmaceuticals Ltd (2018–2026)
Market capitalization of Kiniksa Pharmaceuticals Ltd from 2018 to today. Between 2018 and today, Kiniksa Pharmaceuticals Ltd's market cap moved from $1.36 Billion to $ 4.71 Billion, with a yearly change of 21.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.71 Billion | +136.51% |
| 2025 | $1.99 Billion | +108.54% |
| 2024 | $955.16 Million | +12.77% |
| 2023 | $846.99 Million | +17.09% |
| 2022 | $723.37 Million | +27.27% |
| 2021 | $568.36 Million | -33.39% |
| 2020 | $853.27 Million | +59.76% |
| 2019 | $534.08 Million | -60.63% |
| 2018 | $1.36 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Kiniksa Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.71 Billion USD |
| MoneyControl | $4.71 Billion USD |
| MarketWatch | $4.71 Billion USD |
| marketcap.company | $4.71 Billion USD |
| Reuters | $4.71 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more